OncoMatch/Clinical Trials/NCT07284589
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Is NCT07284589 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies 68Ga-Dotatate for healthy (controls).
Treatment: 68Ga-Dotatate — The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Cancer type
Neuroendocrine Tumor
Demographics
Prior therapy
Cannot have received: SSTR targeted therapy
Medication & Prior Treatment Exclusions: SSTR targeted therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Nuclear Imaging Institute · Englewood, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07284589 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior SSTR targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 120 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages